Exposure-Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status

• Główni autorzy: Paul Baverel (Autor), Lorin Roskos (Autor), Manasa Tatipalli (Autor), Nancy Lee (Autor), Paul Stockman (Autor), Maria Taboada (Autor), Paolo Vicini (Autor), Kevin Horgan (Autor), Rajesh Narwal (Autor)
• Format: Książka
• Wydane: Wiley, 2019-09-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Tremelimumab, an anti‐cytotoxic T‐lymphocyte antigen‐4 monoclonal antibody that enhances T‐cell activation, was evaluated in a randomized, double‐blind, placebo‐controlled, phase IIb study (NCT01843374) in patients with unresectable malignant mesothelioma. The study demonstrated no clinically meanin...